Effect of glatiramer acetate (Copaxone®) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis

Y. Blanco, E. A. Moral, M. Costa, M. Gómez-Choco, J. F. Torres-Peraza, L. Alonso-Magdalena, J. Alberch, D. Jaraquemada, T. Arbizu, F. Graus, A. Saiz

Research output: Contribution to journalArticleResearchpeer-review

42 Citations (Scopus)

Abstract

We assessed the effect of glatiramer acetate (GA) on the immunophenotypic and cytokine profile and the BDNF production by peripheral blood mononuclear cells, and their association with the clinical response in 19 naïve-treated MS patients prospectively followed-up after GA therapy. Two patients withdrew the therapy. After a median follow-up of 21 months, twelve were considered responders and five as non-responders. Non-responder patients had significant longer disease duration and a higher EDSS score at baseline. In the responder group, a significant decrease in the percentage of INF-γ producing total lymphocytes, CD4+ and CD8+ T cells, and reduced percentage of IL-2 producing CD4+ and CD8+ T cells were observed at 12, 18 and 24 months. These changes were associated with a significant increase in the percentage of CD3+, CD4+ and CD4+CD45RA+ T cells, and BDNF production from month 6 that remained significant throughout the study. We did not observe significant changes in the nonresponder group for any of the parameters studied. Our data suggest that GA treatment induces a downmodulation of proinflammatory cytokines associated with the regulation of the peripheral T cell compartment and with increased production of BDNF that might be related to the clinical response.

Original languageEnglish
Pages (from-to)270-275
Number of pages6
JournalNeuroscience Letters
Volume406
Issue number3
DOIs
Publication statusPublished - 9 Oct 2006

Keywords

  • BDNF
  • Cytokines
  • Glatiramer acetate
  • Immunomodulatory treatment
  • Lymphocyte immunophenotyping
  • Multiple sclerosis

Fingerprint

Dive into the research topics of 'Effect of glatiramer acetate (Copaxone®) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis'. Together they form a unique fingerprint.

Cite this